This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Misonix Schedules First Quarter Fiscal 2012 Financial Results Conference Call; November 9, 2011 At 4:30 P.m. Eastern

FARMINGDALE, N.Y., Nov. 8, 2011 /PRNewswire/ -- Misonix, Inc. (NASDAQ: MSON), a medical device company that designs, manufactures, and markets innovative therapeutic ultrasonic products worldwide for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications, today announced plans to release first quarter ended September 30, 2011 financial results on Wednesday, November 9, 2011.  Michael A. McManus, President and Chief Executive Officer and Richard Zaremba, Senior VP and Chief Financial Officer, will host a conference call at 4:30 p.m. Eastern on Wednesday, November 9, 2011 to discuss the Company's first quarter 2012 financial results.

Shareholders and other interested parties may participate in the conference call by dialing 866 783 2138 (domestic) or 857 350 1597 (international) and entering access code 31240745, a few minutes before the start of the call.  A simultaneous webcast will be available via Misonix's website at www.misonix.com.  The call will be archived on the Company's website for at least 90 days.

A recording of the live-call will be available approximately 2 hours after the event through November 16, 2011.  The dial-in number to listen to the recording is 888 286 8010 or 617 801 6888.  The replay access code is 74394535.

About Misonix:

Misonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices.  Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies.  Addressing a combined market estimated to be in excess of $3 billion annually; Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications.  Additional information is available on the Company's Web site at www.misonix.com.

Investor Relations Contact: Kevin M. McGrathCameron Associates, Inc.212 245 4577 Kevin@cameronassoc.com

SOURCE Misonix, Inc.

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,098.39 +74.33 0.41%
S&P 500 2,117.48 +9.19 0.44%
NASDAQ 5,025.2930 +19.9020 0.40%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs